Page 1

PYC Therapeutics 28 October , 2021 REPORT FOR THE QUARTER ENDED 30 SEPTEMBER 2021 ( Q3 ) COMPLETION OF NON - GLP TOLERABILITY AND SAFETY STUDIES HEADLINE Q3 2021 PROGRESS PYC confirmed successful target engagement in the cell type of interest in rabbit eyes in its co - lead drug development program PYC completed critical tolerability and safety studies in non - human primates - Results are expected in the near future once the histopathology analysis is complete The Q3 milestones achieved further validate and de - risk PYC's drug delivery platform and deep ocular pipeline The Company remains on course to transition to a clinical - stage genetic medicine company in 2022 with its highly scaleable underlying platform technology - PYC Therapeutics PERTH , Australia and SAN DIEGO , California - October 28 , 2021 ( ASX : PYC ) is a biotechnology company which combines two complementary platform technologies : Proprietary drug delivery technology ; and RNA drug design capabilities . Together they are being developed to create a new generation of RNA therapeutics to change the lives of patients with inherited diseases . The Company's initial focus is on blinding diseases of the eye . The Company's co - lead drug candidate is the first disease - modifying therapy for patients with a blinding eye disease called Retinitis Pigmentosa type 11 ( RP11 ) . The RP11 co - lead program is supported by a deep ocular pipeline which share both a common delivery technology and backbone chemistry with the RP11 drug candidate . Critical pieces of PYC's non - clinical RP11 data pack were added in Q3 . The new data demonstrates for the first time that PYC's proprietary RNA drug technology can effectively engage its molecular target in the deepest layer of cells within the retina in a large eye¹ . This data was obtained from in vivo studies that employ the same route of administration that is planned for the Company's upcoming first in human clinical trials . PYC also completed the critical exploratory tolerability and safety assessment in non- human primates with the results of these studies anticipated to be available in the near future . 1 see ASX announcement of 28 September 2021 +618 6151 0994 pyctx.com | ACN 098 391 961 1